Daiichi Sankyo Company, Limited
Stock Price Chart
2026/11/20 13:29 UpdatedPrice Trend
2026/11/20 13:29 UpdatedPrice & Trading Details
2026/11/20 13:29 UpdatedPRICE
TRADING
Analyst Recommendations 17 analysts
Updated 2026/11/01Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/10/30 | ¥35.72 | ¥45.50 | +27.4% |
| 2026/07/31 | ¥42.86 | ¥37.72 | -12.0% |
| 2026/05/11 | ¥45.87 | ¥23.10 | -49.6% |
| 2026/01/29 | ¥39.79 | ¥46.79 | +17.6% |
Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
26.4M | -2.25% | |
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
22.7M | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
17.5M | -2.04% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
12.9M | +1.35% | |
|
MFS SERIES TRUST X-MFS International Growth Fund
|
10.7M | -2.29% | |
|
AMERICAN FUNDS GLOBAL BALANCED FUND
|
7.5M | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
14.6K | -4.74% |
Dividend History 3Years Growth
Updated 2026/11/22| Year | Dividend | Change |
|---|---|---|
| 2027 In Progress | ¥50 | - |
| 2026 | ¥78 | +30.0% |
| 2025 | ¥60 | +20.0% |
| 2024 | ¥50 | +66.7% |
| 2023 | ¥30 | - |
Financial Performance
2026/11/22 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,044,892M | ¥1,278,478M | ¥1,601,688M | ¥1,886,256M |
| Gross Profit | ¥691,491M | ¥914,952M | ¥1,186,366M | ¥1,470,458M |
| Operating Income | ¥73,027M | ¥120,582M | ¥211,589M | ¥331,925M |
| Pretax Income | ¥79,269M | ¥135,334M | ¥243,260M | ¥367,485M |
| Net Income | ¥66,972M | ¥109,188M | ¥200,731M | ¥295,756M |
| EPS | ¥34.91 | ¥56.91 | ¥104.62 | ¥155.87 |
| Operating Margin | 6.99% | 9.43% | 13.21% | 17.60% |
| Balance Sheet | ||||
| Total Assets | ¥2,221,402M | ¥2,508,889M | ¥3,461,135M | ¥3,456,119M |
| Total Equity | ¥1,350,872M | ¥1,445,854M | ¥1,688,173M | ¥1,623,416M |
| Total Liabilities | ¥870,530M | ¥1,063,035M | ¥1,772,962M | ¥1,832,703M |
| Cash | ¥662,477M | ¥441,921M | ¥647,180M | ¥639,838M |
| Interest-bearing Debt | ¥163,461M | ¥143,088M | ¥101,713M | ¥101,332M |
| Equity Ratio | 60.81% | 57.63% | 48.78% | 46.97% |
| D/E Ratio | 0.12 | 0.10 | 0.06 | 0.06 |
| Cash Flow | ||||
| Operating CF | ¥139,226M | ¥114,514M | ¥599,258M | ¥53,842M |
| Investing CF | ¥212,339M | -¥257,782M | -¥282,636M | ¥334,170M |
| Financing CF | -¥86,231M | -¥89,594M | -¥123,564M | -¥377,769M |
| Free CF | ¥62,544M | ¥47,148M | ¥476,467M | -¥134,030M |
| Efficiency | ||||
| ROE | 4.96% | 7.55% | 11.89% | 18.22% |
| ROA | 3.01% | 4.35% | 5.80% | 8.56% |
Latest IR Information
-
Supplementary Financial Materials (Fiscal Year 2026 Q2 Results)
Supplementary materials for the Fiscal Year 2026 Q2 results. Revenue shows a structure below the prior year, while core operating profit increased. Includes analysis of foreign exchange effects, contributions from new businesses, and segment trends such as EU specialty.
Read more -
Consolidated Financial Results for 2Q FY2026
Cumulative results for 2Q FY2026 show sales revenue up +19.7% YoY and operating income up +34.4% YoY. No revision to full-year forecast. Growth driven by key products ENHERTU and Tarlatamab. Reviewed and corrected CMO loss compensation items. Strengthening financial soundness...
Read more -
Daiichi Sankyo Company, Limited Financial Summary for the Six Months Ended March 2027 (IFRS, Consolidated)
Interim revenue was 1,167,233 million yen, up 19.7% year-over-year. Core operating profit was 221,331 million yen, up 46.9%; operating profit was 193,795 million yen; interim profit was 151,534 million yen. For fiscal 2027 the dividend policy anticipates a full-year dividend...
Read more -
Notice of Filing an Appeal Against NTK's Claim for Damages and Other Relief
NTK filed an appeal, moving the case to the Tokyo High Court. The lower court ruled in favor of Daiichi Sankyo. The appeal concerns claims totaling 2,033 hundred million yen; the impact on future results is under review.
Read more -
Notice of judgment on the damages claim lawsuit from NTK against us (win)
The Tokyo District Court recognized Daiichi Sankyo's arguments against NTK's claim and dismissed all of NTK's claims. The judgment date is September 10, 2026. There is currently no direct impact on our earnings.
Read more
Latest News (5 items)
-
Average Analyst Rating: strong_buy
Average Target Price: ¥4,021
Rating Score: 1.50 (Based on 17 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.